Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Ethinylestradiol/norgestimate (Primary) ; Evacetrapib (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2013 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.